| DC58046 |
C12-200
Featured
|
C12-200 is a well-known cationic lipid used in the formulation of lipid nanoparticles (LNPs) for the delivery of therapeutic nucleic acids, including siRNA, mRNA, and CRISPR components. It is widely recognized for its high in vivo potency at low doses and is often used as a positive control ionizable lipid in research exploring new ionizable lipids. |
|
| DC58047 |
DSPE-PEG 2000
Featured
|
PEG2000-DSPE is used for creating micelles that are able to carry drugs with low solubility. |
|
| DC60184 |
AZ194
Featured
|
AZ-194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1]. |
|
| DC60185 |
Giredestrant (tartrate)
Featured
|
Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. |
|
| DC60186 |
Difelikefalin HCl
Featured
|
Difelikefalin is a κ-opioid receptor (KOR) agonist. It activates KOR in HEK293 cells expressing the human receptor (EC50 = 0.16 nM in a transactivation assay) and inhibits forskolin-induced cAMP production in R1.G1 mouse thyoma cells (EC50 = 0.048 nM). Difelikefalin is selective for KOR over the μ-opioid receptor. |
|
| DC60187 |
SWN41522
Featured
|
SWN41522, also known as DUPA and FN11, is a potent Urea-Based Inhibitor of Glutamate Carboxypeptidase II (NAALADase). In vivo antitumor tests using U-87 glioblastoma xenograft showed that FN11 reduced tumor vol. to a value of ∼0.4-0.6 (at 10 or 100 μM) after 4 days treatment, and ∼ 1.0 (at both dosages) after 7 days treatment. The antiangiogenesis activity of FN11 was examd. with similarly grown tumors, and revealed a preponderance of avascular and low vascular areas in tumors treated with FN11 at 100 μM. It was first reported in patent WO 2000064911 and Journal of Medicinal Chemistry (2001), 44(3), 298-301. |
|
| DC60188 |
RTICBM-189
Featured
|
RTICBM-189 is a Urea derivative and a CB1 allosteric modulator. RTICBM-189 showed no activity at >50 protein targets and excellent brain permeation but relatively low metabolic stability in rat liver microsomes. Pharmacokinetic studies in rats confirmed the excellent brain exposure of 31 with a brain/plasma ratio Kp of 2.0. Importantly, intraperitoneal administration of RTICBM-189 significantly and selectively attenuated the reinstatement of the cocaine-seeking behavior in rats without affecting locomotion. |
|
| DC58055 |
P300/CBP-IN-3
Featured
|
P300/CBP-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1[1]. |
|
| DC60189 |
CDDO-dhTFEA
Featured
|
|
|
| DC60190 |
TAS4464
Featured
|
TAS4464 is a highly potent and selective inhibitor of NEDD8 (IC50 of 0.955 nM). TAS4464 selectively inhibited NAE relative to the other E1s UAE and SAE. TAS4464 treatment inhibited cullin neddylation and subsequently induced the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IκBα in human cancer cell lines. TAS4464 showed greater inhibitory effects than those of the known NAE inhibitor MLN4924 both in enzyme assay and in cells. |
|
| DC60191 |
Tenofovir Alafenamide Impurity 1
Featured
|
|
|
| DC60194 |
Derazantinib dihydrochloride
Featured
|
Derazantinib is a multi-kinase inhibitor with pan-FGFR activity which has shown preliminary therapeutic activity against FGFR2 fusion-positive intrahepatic cholangiocarcinoma (iCCA). Derazantinib dihydrochloride is a salt of Derazantinib. |
|
| DC60195 |
Batefenterol Succinate
Featured
|
Batefenterol Succinate is a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties. |
|
| DC60196 |
K-Ras G12C-IN-4
Featured
|
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS. |
|
| DC60197 |
Pinacol
Featured
|
|
|
| DC60198 |
GN44028
Featured
|
GN44028 inhibits HIF-1α. GN44028 surpresses HIF-1α transcriptional activity without affecting both HIF-1α protein accumulation and HIF-1α/HIF-1β heterodimerization in nuclei under the hypoxic conditions, suggesting that GN44028 probably affectes the transcriptional pathway induced by the HIF-1α/HIF-1β heterodimer. |
|
| DC60199 |
Bifluranol
Featured
|
Bifluranol (brand name Prostarex; former developmental code name BX-341) is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol that has been used as an antiandrogen in the United Kingdom in the treatment of benign prostatic hyperplasia. It exerts functional antiandrogen effects by binding to and activating the estrogen receptor in the pituitary gland, consequently suppressing the secretion of luteinizing hormone (and hence acting as an antigonadotropin) and thereby reducing gonadal androgen production and systemic androgen levels. |
|
| DC60200 |
SEP-363856 isomer
Featured
|
R isomer of SEP-363856. |
|
| DC58060 |
VV116 (non-deuterated)
Featured
|
non-deuterated form of VV116.VV116 is an oral drug candidate of nucleoside analog against SARS-CoV-2. |
|
| DC58062 |
4-Nitrophenylrhamnoside
Featured
|
4-Nitrophenyl α-L-rhamnopyranoside is a chromogenic substrate for naringinase. |
|
| DC58063 |
HG106
Featured
|
HG106 is a potent SLC7A11 inhibitor and enhances ROS generation, ER stress, and ultimately growth arrest specifically in KRAS-mutant lung adenocarcinoma (LUAD). |
|
| DC58110 |
Dclk1-IN-1
Featured
|
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1+ pancreatic ductal adenocarcinoma (PDAC)[1]. |
|
| DC47877 |
tri-GalNAc-COOH (acetylation)
Featured
|
tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC. |
|
| DC47881 |
TMX-4116
Featured
|
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC50s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma. |
|
| DC47884 |
TLR4-IN-C34-C2-COOH
Featured
|
TLR4-IN-C34-C2-COO is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis. |
|
| DC47886 |
Thalidomide-Piperazine 5-fluoride
Featured
|
Thalidomide-Piperazine 5-fluoride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. |
|
| DC47894 |
SR-0813
Featured
|
SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC50 and EC50 values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC50 and EC50 values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (Kd=3.5 μM) than ENL YEATS (Kd=30 nM). SR-0813 can be used for the research of acute leukemia. |
|
| DC47917 |
PW0787
Featured
|
PW0787 is a potent, selective, orally active, and brain-penetrant GPR52 agonist (EC50=135 nM). PW0787 suppresses psychostimulant behavior. |
|
| DC47928 |
PCC0208017
Featured
|
PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability. |
|
| DC47938 |
NCT-58
Featured
|
NCT58(NCT 58) is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells. |
|
